12th World ADC London 2022

Temi della conferenza
With the approvals of Zynlonta and Tivdak within the last 12 months there are now 11 commercially available ADCs on the market. Furthermore, recent Enhertu and Polivy data suggests that ADCs could be soon be used as earlier line treatments to improve patient outcomes sooner. Undoubtedly, the momentum and inspiration that ADCs and ADC developers are gathering means that it's an incredibly exciting time for the entire community.

Professional congress organizer (PCO)
Hanson Wade

Annotazioni
URLs:
Brochure: https://go.evvnt.com/944846-3?pid=4832
LinkedIn: https://go.evvnt.com/944846-4?pid=4832
Twitter: https://go.evvnt.com/944846-5?pid=4832

Speakers: Sunil Verma, Global Head and Head of Breast Cancer Strategy, AstraZeneca, and more.

https://go.evvnt.com/944846-2?pid=4832

Mr. Hanson Wade